Patent SG-11201907561P-A (SG)
Title: Anti-lag-3 antibodies and uses thereof
Inventor: FANG LEI
IPC: C07K16/28
Filed: 2018-02-22
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 30 August 2018 (30.08.2018) WIPO I PCT IiiimmoimmonotiolomonllnolomolioluovoimIE (10) International Publication Number WO 2018/153340 Al (51) International Patent Classification: A61K 39/00 (2006.01) Cl 2N 15/13 (2006.01) C07K 16/28 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/CN2018/076940 (22) International Filing Date: 22 February 2018 (22.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PCT/CN2017/074365 22 February 2017 (22.02.2017) CN PCT/CN2017/088570 16 June 2017 (16.06.2017) CN (71) Applicant: I-MAB; Grand Pavilion, Hibiscus Way, 802 West Bay Road, PO Box 31119, Cayman KY1-1205 (KY). (72) Inventors: FANG, Lei; Suite 802, West Tower, OmniVi- sion, 88 Shangke Road, Shanghai 201206 (CN). WANG, Zhengyi; Suite 802, West Tower, OmniVision, 88 Shangke Road, Shanghai 201206 (CN). GUO, Bingshi; Suite 802, West Tower, OrrmiVision, 88 Shangke Road, Shanghai 201206 (CN). ZANG, Jingwu; Suite 802, West Tower, OmniVision, 88 Shangke Road, Shanghai 201206 (CN). JIANG, Wenqing; Suite 802, West Tower, OmniVi- sion, 88 Shangke Road, Shanghai 201206 (CN). WANG, Yongqiang; Suite 802, West Tower, OrrmiVision, 88 Shangke Road, Shanghai 201206 (CN). (74) Agent: SHANGHAI BESHINING LAW OFFICE; 21st Floor Sfeco Mansion 681 Xiaomuqiao Road, Shanghai 200032 (CN). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) 1-1 0 (57) : Provided are antibodies that bind Lymphocyte Activation Gene-3 (LAG-3). Also provided are methods of stimulating \" an immune response, inhibiting growth of tumor cells, and treating an autoimmune, inflammatory, or viral disease. (54) Title: ANTI-LAG-3 ANTIBODIES AND USES THEREOF